AI drug discovery companies

Generate:Biomedicines uses machine learning and experimental protein engineering to design biologic medicines. Its Somerville, Massachusetts operations support an owned pipeline and partner programs. The current pipeline places GB-0895, an antibody against TSLP, in Phase 3 for severe asthma and Phase 1 for COPD. It also lists GB-4362 in Phase 1 alongside antibody-drug conjugates and GB-5267, a Roswell Park-partnered CAR T-cell therapy, in Phase 1 for ovarian cancer.

Generate priced a $400 million IPO on 26 February 2026, stating expected gross proceeds before fees. Its October 2026 Zealand Pharma collaboration covers AI-engineered protein therapies for metabolic diseases.

The pipeline also lists preclinical programs, including antibody-drug conjugates. It describes GB-0895 as an extended-half-life antibody being studied for twice-yearly dosing. The clinical program is evaluating that dosing approach; the pipeline also includes a separate Phase 1 study in COPD.

Insilico Medicine develops the Pharma.ai software suite and its own AI-discovered drug pipeline. PandaOmics identifies and prioritizes targets, while Chemistry42 generates and optimizes small molecules. Its programs span fibrosis, cancer, immunology and metabolic disease.

The lead rentosertib program entered the Phase 3 GENESIS-IPF-3 trial, with first patient dosing announced in September 2026. Rentosertib, also called ISM001-055 or INS018_055, inhibits TNIK and is being studied for idiopathic pulmonary fibrosis. The randomized, double-blind study evaluates once-daily treatment over 52 weeks. This later announcement updates a pipeline page that still describes Phase 2a completion.

Insilico identifies Boston and Hong Kong as its headquarters and names Sanofi, Exelixis and Fosun Pharma among drug-development collaborators. It listed in Hong Kong on 30 December 2025. The company’s case-study page reports approximately $293 million raised in the IPO. That public-market financing is separate from licensing payments and potential milestone totals in its pharma agreements.

MindRank uses AI to discover and optimize small-molecule medicines. Its Molecule Pro platform supported the design of MDR-001, an oral GLP-1 receptor agonist for obesity and type 2 diabetes. The company announced first patient dosing in the Phase 3 MOBILE trial in China on 26 February 2026, following Phase 2b work in obesity. The randomized, double-blind, placebo-controlled study was planned to enroll about 750 patients at 50 clinical centers, with Peking University People’s Hospital as lead site.

The Hangzhou company announced a $52 million Series B in July 2026. That release describes its Molecule Arts Platform as an integrated research system combining biology, chemistry, computation, experimental evidence and clinical learning. It also reports three IND clearances and five additional preclinical development candidates, without assigning all of those programs to a single trial phase.

Its September 2026 agreement with 3SBio covers commercialization of MDR-001 in China. MindRank also lists earlier Antengene and Medicilon discovery relationships in its company history.

Relay Therapeutics combines molecular dynamics, machine learning and laboratory experiments in its Dynamo drug-design platform. Its lead zovegalisib, formerly RLY-2608, is a mutant-selective PI3Kα inhibitor in the Phase 3 ReDiscover-2 breast-cancer trial. The registry was updated on 5 November 2026.

The Cambridge, Massachusetts company is listed on Nasdaq as RLAY. Its Pfizer supply agreement provides atirmociclib for a planned frontline breast-cancer trial. Relay retains global rights to zovegalisib. It priced a $275 million public share offering on 20 May 2026, before fees and any underwriter option.

Schrödinger uses physics-based molecular simulation and AI to design drugs. Its most advanced investigational collaboration is zasocitinib, co-invented with Nimbus and now owned by Takeda. After Phase 3, its psoriasis application entered FDA Priority Review in September 2026. Its internal leads, SGR-1505 and SGR-3515, remain in Phase 1.

The New York company is listed on Nasdaq as SDGR. Its drug-discovery partners include Lilly, Bristol Myers Squibb, Novartis and Otsuka. Its latest disclosed market fundraising was $8.9 million gross from share sales in 2024. The unused share-sale facility is financing capacity. Tectora’s $55 million Series A in 2026 financed a separate company co-founded by Schrödinger.

Absci uses AI and laboratory experiments to design antibodies and find targets. Its lead ABS-201 targets the prolactin receptor and is in Phase 1/2a for androgenetic alopecia. The company also lists an endometriosis program for ABS-201.

Its June 2026 filing describes a stock offering of 13,495,277 shares at $7.41 each, expected to close on 25 June. The homepage names AstraZeneca, Merck and Almirall among collaborators. Its corporate headquarters are in Vancouver, Washington.

Biolojic Design uses machine learning to engineer antibodies, including molecules that bind two targets through the same Fab. Its headquarters are in Ness Ziona, Israel.

The company’s Aulos Bioscience partnership developed AU-007, also called imneskibart, in a Phase 1/2 cancer trial. Its 2026 pipeline updates describe a Teva preclinical milestone for TEV-325, formerly BD9, which targets IL-13 and TSLP. Merck KGaA is another discovery partner. A latest corporate financing amount and date were not verified.

Earendil Labs uses AI to design antibodies and other biologics for autoimmune disease and cancer. Its lead HXN-1001, an anti-TL1A antibody, entered a Phase 2a ulcerative-colitis trial, with first patient dosing announced on 2 April 2026. The company also reported completion of enrollment in its Australian Phase 1 study.

Earendil announced $787 million raised across financing rounds in March 2026. Its Sanofi agreement covers bispecific antibodies for autoimmune and inflammatory bowel diseases.

Enveda uses AI to identify drug molecules in nature and is based in Boulder, Colorado. Its lead ENV-294 is in Phase 2 for atopic dermatitis, with the registry updated on 25 September 2026. A separate Phase 2 asthma study is also recruiting.

The company announced a $311 million Series E on 23 September 2026, led by Catalio Capital Management. ENV-294 has advanced beyond the Phase 1 results cited earlier.

Evaxion uses AI-Immunology to identify antigens and design vaccines for cancer and infectious diseases. It operates from Hørsholm, Denmark, and is listed on Nasdaq as EVAX. Its personalized cancer vaccine EVX-01 reached Phase 2 in combination with pembrolizumab for advanced melanoma. The registry now lists that study as completed, with an update posted on 4 November 2026.

The company’s presentation describes its MSD vaccine partnership. Phase 2 remains the most advanced documented stage for EVX-01.

Healx uses its Healnet AI engine to find small-molecule treatments for rare diseases. Based in Cambridge, UK, it combines disease biology, experimental profiling and computational predictions. Its latest financing located was the same announcement’s $47 million Series C on 1 August 2024, co-led by R42 Group and Atomico.

The company announced first dosing in the Phase 2 INSPIRE-NF1 study of HLX-1502 on 24 February 2025. It later announced first dosing of HLX-4310 in a Phase 1/2 sarcoma trial on 22 July 2026, working with the National Pediatric Cancer Foundation’s Sunshine Project. A named pharma discovery partner was not established.

Juvena Therapeutics uses JuvNET, an AI and multi-omics platform, to identify secreted proteins and engineer regenerative medicines. Its lead JUV-161 is an IGF2-derived protein for muscle disease. The company reports completion of Phase 1 in healthy volunteers and an enrolling Phase 1/2 study in experimentally induced muscle atrophy.

Its January 2026 financing was a $33.5 million Series B led by Bison Ventures. Juvena’s news page dates its Lilly muscle-health collaboration to June 2025, and its company profile gives Redwood City, California as headquarters.

Lantern Pharma uses its RADR AI platform, machine learning and genomics in small-molecule oncology development. Its lead LP-300 is in the Phase 2 HARMONIC study for never-smoker non-small cell lung cancer; LP-184 and LP-284 are additional clinical programs.

The Dallas company lists its address in its investor materials. On 30 September 2026 it announced closing of a stock offering with approximately $4 million gross proceeds and a further $4 million conditional on warrant exercise. A named pharma discovery partnership was not verified.

Recursion uses machine learning and automated experiments to connect biological changes with potential medicines, from its Salt Lake City base. Its lead REC-4881 is an oral MEK1/2 inhibitor in Phase 2 for familial adenomatous polyposis. The company identified this use through phenotypic research. Its pipeline also lists the RBM39 degrader REC-1245 in Phase 1 for solid tumors and lymphoma, and the reversible, brain-penetrant LSD1 inhibitor REC-4539 in Phase 1 for oncology indications.

Exscientia became a wholly owned Recursion subsidiary when their combination completed on 20 November 2024. The resulting business combines experimental biology with computational chemistry and AI design. This entry covers the combined company.

Recursion announced a $200 million underwritten stock offering on 15 October 2026. Its November 2026 update reports continued work with Sanofi and Genentech, including Sanofi’s option on a development candidate and Genentech’s advancement of a neuroscience target. That update also names Fred Hassan as chair, effective 31 October.

Valo Health uses human data, AI and predictive chemistry to discover small molecules. The Lexington, Massachusetts company works with Novo Nordisk on cardiometabolic disease and Merck KGaA on Parkinson’s disease.

Its most advanced documented drug, OPL-0401, reached Phase 2 in diabetic retinopathy. Valo reported that SPECTRA missed its primary and secondary endpoints on 31 December 2024 and said it was seeking a development partner. The registry has an unknown recruitment status. Continued clinical development has not been announced.

Accutar Biotech uses AI molecular modeling followed by laboratory validation to discover drugs. It lists a Cranbury, New Jersey address. Its AC699 oral estrogen-receptor degrader had Phase 1 breast-cancer results published in December 2025.

The company announced 2026 milestones with Evommune and Cytokinetics, plus a July 2026 joint-company agreement with HEC Pharm. Its latest financing announcement located dates to April 2021 and gives cumulative funding above $100 million, with no separate round amount.

BigHat Biosciences designs antibodies with machine learning and an automated laboratory platform called Milliner. Based in San Mateo, California, it develops owned and partnered protein therapeutics. Its CDH17-directed antibody-drug conjugate BHB810 entered Phase 1, with first dosing announced on 1 September 2026, initially in gastric and gastroesophageal cancers.

BigHat announced a $75 million Series C on 24 September 2026. That followed a $44 million Series B extension in 2025. Its 2026 announcements also name Lilly and Merck collaborations, while an October 2025 update records completion of its Johnson & Johnson collaboration.

Biolexis Therapeutics uses AI-driven design to develop oral small molecules for metabolic disease from Lehi, Utah. The company says BLX-7006, a GLP-1 receptor agonist, and BLX-0871, an AMPK activator, have completed Phase 1. Their BLX-7006 and BLX-0871 registry records still say recruitment has not started; both were last updated on 24 August 2025.

Its November 2023 financing announcement reported a $10 million Series A, led by Clarke Capital. Phase 1 completion remains a company-reported claim.

Cellarity uses multi-omics data and AI models of cell states to discover small-molecule medicines. Its lead CLY-124 entered a Phase 1 proof-of-concept study in sickle cell disease in 2025. The January 2026 update also describes a MASH program with Novo Nordisk and work in myelofibrosis.

Based in Somerville, Massachusetts, Cellarity announced its latest named financing located, a $121 million Series C, on 4 October 2022.

CHARM Therapeutics uses DragonFold, its AI protein-ligand co-folding platform, to design small-molecule drugs. The London company announced dosing of its menin inhibitor CHM-029 in October 2026. It calls the study Phase 1/2; the registry classifies the current study as Phase 1, with an update on 26 October 2026. The trial enrolls patients with genetically defined acute myeloid leukemia.

CHARM announced an $80 million Series B on 2 September 2025, co-led by NEA and SR One.

Iambic uses its Enchant and NeuralPLexer AI technologies with automated chemistry and biology to design small-molecule medicines. The San Diego company’s lead IAM1363 is a brain-penetrant HER2 inhibitor in Phase 1/1b for HER2-altered cancers, with updated data announced on 26 October 2026.

It priced its IPO on 14 October 2026 for expected gross proceeds of $150 million. Its 2026 news archive records drug-discovery collaborations with Bayer and AbbVie.

Montai Therapeutics uses its CONECTA AI platform to discover oral drugs for inflammatory disease. It is based in Cambridge, Massachusetts, and explores diverse chemical structures against targets that have been difficult to address with small molecules.

The company announced first participants dosed in a Phase 1 trial of MTAI-1025 on 1 October 2026. MTAI-1025 is an oral NRF2 agonist being developed for ulcerative colitis.

Its latest funding disclosure established here remains Flagship Pioneering’s initial $50 million commitment at launch in December 2022. This was a commitment, with no later completed round verified. A named pharma discovery partnership was not established.

Pharos iBio uses Chemiverse, its AI and big-data platform, to develop drugs for rare and refractory diseases. Its 2026 BIO KOREA company profile describes lasmotinib, PHI-101, preparing for Phase 2 in acute myeloid leukemia, with ovarian-cancer and PHI-501 solid-tumor programs in Phase 1.

The latest financing verified was KRW19 billion in convertible bonds, reported closed in December 2025. It proposed moving headquarters from Anyang to Seoul in March 2026. The homepage had no readable text; completion of the relocation and a named pharma discovery partner were not verified.

ProteinQure designs peptides and peptide-drug conjugates with ProteinStudio, which combines AI models and molecular simulation. The Toronto company’s lead PQ203 targets sortilin to deliver a cytotoxic payload into cancer cells. It announced first patient dosing in Phase 1 for advanced metastatic cancer on 17 September 2025.

ProteinQure closed an $11 million Series A announced on 28 May 2025, led by Tom Williams of Heron Rock Fund. Its partnering work includes AstraZeneca, while internal discovery also covers kidney and brain delivery.

Superluminal Medicines uses AI, protein dynamics and structural biology to design small molecules against GPCRs. The Boston company has registered a Phase 1 study of SUN-0864 in healthy adults and adults with overweight or obesity. The record, posted on 29 October 2026, says recruitment has not started and estimates a November 2026 start.

Superluminal announced a $60 million Series B on 3 September 2026, led by BVF Partners. Lilly participated as an investor.

Ainnocence designs antibodies, peptides and small molecules with sequence-based AI models. Its Mountain View, California headquarters supports platforms including SentinusAI and CarbonAI. The pipeline offers autoimmune, oncology, metabolic and CNS programs for licensing, without establishing a named clinical lead. Its news archive records 2025 platform launches and 2026 antibody-engineering work. A completed funding round and named pharma development partner were not verified.

Aitia uses its Gemini Digital Twin platform to model human disease and identify drug targets. It combines causal AI, multi-omics data and simulation for oncology and neurological diseases. The company lists a Cambridge, Massachusetts address.

Its September 2026 Ono Pharma agreement covers neurological target discovery; other named partners include Servier and Orion. The latest financing established was a January 2020 extension taking the former GNS Healthcare’s Series D to $28 million. A current named clinical lead was not verified.

Antiverse designs antibodies against GPCRs, ion channels and other membrane targets with generative AI and laboratory experiments. It is headquartered in Cardiff.

The company raised a $9.3 million Series A in March 2026. Its news page names Nxera Pharma as a discovery partner. A named internal lead or clinical phase was not established; the financing supports antibody discovery and preclinical development.

Aqemia uses generative AI and physics to invent small-molecule medicines. It has offices in Paris and London and runs owned and partnered discovery programs, using external laboratories for experiments. No named lead or human trial phase appears on that pipeline page.

Its Sanofi collaboration expanded in July 2026. The latest equity round located was $38 million in December 2024, led by Cathay Innovation. Aqemia subsequently announced a separate $7.4 million grant in April 2025 for epitranscriptomics and RNA-targeting work.

Chai Discovery builds AI models for molecular structure prediction and de novo drug design, including therapeutic antibodies. Its headquarters are in San Francisco.

It announced a $400 million Series C on 14 July 2026. Its 2026 pharma agreements include Lilly, Pfizer, Novartis, argenx, Bristol Myers Squibb, GSK and a Roche collaboration announced on 5 November. No company-owned lead clinical candidate was established.

Deargen uses its Dr.UG deep-learning platform for target discovery, molecular selection and lead optimization. It lists offices in Seoul and Daejeon; a designated headquarters was not established. The company reported a $17 million Series B in February 2022. Its updates include a JW Pharmaceutical research agreement and a March 2026 shareholder-meeting notice. A named lead clinical asset or trial phase was not verified.

DeepCure develops small molecules for immune and inflammatory diseases. Its current pipeline lists oral BRD4-BD2 and STAT6 programs in IND-enabling studies. The STAT6 development candidate DC-15442 was announced in June 2025.

Based in Boston, DeepCure closed a $24.6 million Series A-1 in April 2024, led by IAG Capital Partners. No named pharma discovery partner or first human dose was established.

Denovo Sciences develops AI software for small-molecule design, ADMET assessment and synthesis planning in Yerevan. Its site describes experimentally tested antiviral molecules without identifying a clinical lead. An investor interview in 2025 reports a $1 million Alchemist Doha investment. A named pharma discovery partner was not verified. A newer funding round or human trial stage was not established.

Evozyne designs therapeutic proteins with generative AI and high-throughput experiments. Its programs cover IgG proteases, engineered cytokines and respiratory disease. The pipeline describes preparation for a first IND submission in 2026, with human dosing to follow; it does not establish that dosing has started.

The Chicago company’s latest financing located was an $81 million Series B in September 2023. Its partnership page describes prior protein-design work with Takeda, while Takeda’s March 2026 reporting says that collaboration has concluded.

Galux designs protein therapeutics with its GaluxDesign AI and physics platform and has its headquarters in Seoul. Its 2026 collaborations include Dong-A ST on antibodies for antibody-drug conjugates, GC Biopharma on autoimmune antibodies and OliX on siRNA delivery.

It announced a $29 million Series B on 10 February 2026. The reviewed material describes protein design and laboratory validation without identifying a lead clinical candidate or trial phase.

Genesis Molecular AI combines foundation models and physics in GEMS, its drug-design platform. Its owned pipeline includes preclinical oncology and immunology work, with pan-mutant PIK3CA inhibitors approaching development-candidate nomination.

Its latest broad venture round located was a $200 million Series B in 2023. More recently, the 2026 expansion with Incyte brought aggregate upfront consideration across their agreements to $150 million, including a $40 million equity investment. Gilead is another named discovery partner. Its company profile gives Burlingame, California as headquarters.

Gero combines longitudinal human health data, physics-informed AI and molecular design to discover drugs for age-related disease. Its June 2026 announcement reports $17 million in new financing, bringing total equity funding to $34 million.

The release describes preclinical pipeline work and partnerships with Chugai and Pfizer. It does not name a clinical lead. Gero identifies Singapore as its headquarters.

Iktos combines Makya, its generative molecule-design software, Spaya retrosynthesis software and automated chemistry and biology to discover small-molecule drugs. The Paris company added an oncology collaboration with Irimajiri Therapeutics in October 2025.

Its latest equity round located was €15.5 million in March 2023, co-led by M Ventures and Debiopharm Innovation Fund. The reviewed pipeline does not establish a named lead drug or clinical phase.

insitro combines machine learning, human genetics and automated cellular experiments to find disease targets and design medicines. The South San Francisco company works across metabolic disease, neuroscience and ophthalmology. Its liver fat and fibrosis programs CTRO-1013 and CTRO-1029 are in IND-enabling studies, while its ALS and dry age-related macular degeneration programs remain earlier in discovery.

In October 2026, AstraZeneca agreed to collaborate on MASH and cardiomyopathy targets and therapeutics. insitro also reports work with Bristol Myers Squibb and Lilly. Its latest named equity round located was a $400 million Series C, announced on 15 March 2021.

Isomorphic Labs builds predictive and generative models for drug design, extending the work behind AlphaFold to small molecules and biologics. Its pharma partners include Novartis, Eli Lilly and Johnson & Johnson. Novartis expanded its research agreement in February 2025; Johnson & Johnson joined in January 2026.

The London company raised $2.1 billion in a Series B led by Thrive Capital on 12 May 2026, with Alphabet and GV among the returning investors. That announcement describes programs progressing toward the clinic. It does not name a lead candidate or establish a human trial stage.

Kimia Therapeutics uses ATLAS, which combines machine learning, automated synthesis and screening, to discover small-molecule drugs. It is based in Berkeley, California, and works in oncology and immunology.

On 4 November 2026, Kimia announced an agreement with CStone Pharmaceuticals to develop KT-721 in China and Australia. The announcement places first dosing in early 2027 and does not confirm an IND filing. KT-721 remains in the preclinical section. Kimia retains global rights. Its December 2023 Series A raised $55 million.

LabGenius Therapeutics uses machine learning and automated experiments to design antibodies. Its London team develops multispecifics for solid tumors. The lead LGTX-101, a Nectin-4 × CD3 T-cell engager, is in IND-enabling studies.

LabGenius raised £35 million in a Series B announced on 21 May 2024, led by M Ventures. It announced an LG Chem antibody-discovery agreement in June 2026 and a new Sanofi collaboration in December 2025.

Manifold Bio combines AI protein design with barcodes that let researchers measure many biologics in living animals. Its pipeline focuses on tissue delivery, starting with brain shuttles and programs against amyloid beta, tau and alpha-synuclein. The site describes discovery, optimization and IND-enabling work without identifying a named clinical lead.

The Boston company announced a $40 million Series A on 14 July 2022. Its news archive records a November 2025 Roche brain-shuttle collaboration and the September 2026 mBER-2 design platform release.

Model Medicines uses GALILEO, its AI discovery engine, to design small molecules for viral diseases and other indications. Its lead antiviral MDL-001 targets the RdRp Thumb-1 pocket and is in IND-enabling work, with an IND submission listed for 2027. MDL-4102, a selective BRD4 inhibitor, is in preclinical proof-of-concept work.

An October 2026 Form D gives San Diego as the principal business address and reports $5,115,268 sold in an $8 million equity offering, with first sale on 15 October. A named pharma development partner was not established.

Nabla Bio designs biologics using generative AI, laboratory testing and proprietary experimental data. Based in Cambridge, Massachusetts, it offers platform collaborations and molecules for licensing. Its second Takeda collaboration was announced in October 2025.

The latest financing located was a $26 million Series A in May 2024. The company’s partnering page describes a portfolio of designed biologics without naming a lead clinical candidate or trial phase.

Noetik builds AI models from human tumor data to discover cancer targets and study treatment response. It is based in South San Francisco. Its work includes both therapeutic discovery and patient selection, and the reviewed sources do not name a Noetik-owned clinical candidate.

Its news archive records a $40 million Series A in August 2024, an Agenus biomarker collaboration in June 2025 and GSK model licensing in January 2026. The GSK agreement concerns AI foundation models; Agenus’s BOT/BAL drugs are partner assets.

PharmEnable Therapeutics uses AI to design small molecules for difficult and data-sparse targets. Its pipeline includes dual-CDK, OX1, CD73 and KRAS programs without identifying a lead clinical candidate.

The Cambridge, UK company closed a $7.5 million pre-Series A announced on 22 May 2023, the latest round verified here. MP Healthcare Venture Management led the round. A current named pharma discovery partnership was not verified from the reviewed pages.

Phenomic AI uses machine learning and single-cell transcriptomics to identify tumor targets and develop medicines. Its lead is a CD3 engager at the development-candidate stage for solid tumors. The company has not disclosed the candidate’s name or a human trial.

Phenomic is based in Toronto. Its company page records a $6 million seed financing at its October 2020 launch and November 2023 collaborations with Boehringer Ingelheim and Xyphos, an Astellas subsidiary. It belongs in the platforms and preclinical section.

PostEra uses Proton, its machine-learning medicinal-chemistry platform, to discover and develop small-molecule drugs. It works with Pfizer and Amgen. C&EN identifies Cambridge, Massachusetts as its headquarters and reports a $24 million Series A in 2022, the latest equity round established here.

In September 2026, Merck KGaA acquired PostEra’s fertility programs, which included FSH-receptor agonists for ovarian stimulation. The announcement concerns those programs; the reviewed sources do not establish a new owner for PostEra itself. A current company-owned lead clinical stage was not verified.

Proxima uses generative AI and structural-proteomics data to design proximity-based medicines, including molecular glues and other ways to change protein interactions. It launched its Neo-1 model in March 2025 and announced an $80 million seed round led by DCVC on 13 January 2026.

Its news archive names Bristol Myers Squibb, Blueprint Medicines and Halda Therapeutics collaborations. It does not establish a named lead drug or clinical phase. Its headquarters are listed as New York City.

Tahoe Therapeutics now presents its business as Tahoe Labs, building single-cell perturbation datasets and AI models of drug response. It is based in South San Francisco and was previously Vevo Therapeutics.

Tahoe announced $30 million in funding led by Amplify Partners on 11 August 2025. In January 2026 it agreed with Alloy Therapeutics to form a company for antibody-drug conjugates against two solid-tumor targets. That announcement describes discovery-stage development; no named clinical lead or first dose was established.

Terray Therapeutics builds hardware, experimental datasets and AI models for small-molecule discovery. Its pipeline separates internal and partnered medicines without giving a named lead or clinical phase.

The company closed a $120 million Series B announced on 17 October 2024, led by Bedford Ridge Capital and NVentures. Its December 2025 update records a discovery milestone with Bristol Myers Squibb, and it has a multi-target Gilead collaboration. A California state financing-agency document identifies Pasadena as headquarters.

Variational AI’s Enki generates small molecules against specified targets and optimizes properties such as potency, selectivity and pharmacokinetics. The Vancouver company raised a $5.5 million seed extension in February 2025, led by Nimbus Synergies.

Its 2026 work includes SK Life Science Labs and a Rakovina ATR-inhibitor case study. The latter describes a candidate-ready preclinical program. A Variational-owned clinical lead was not established.

Verge Labs, previously Verge Genomics, builds AI models of human neurological disease. The San Francisco company works on target discovery, program assessment and patient selection. Its partners include Lilly, Alexion/AstraZeneca and Tenacia.

Its PIKfyve inhibitor VRG50635 reached Phase 1b in ALS, but the trial was terminated for lack of risk-benefit data. The registry was updated on 15 December 2025. Verge now offers its vBx model to other drug developers. It has not disclosed a replacement clinical lead.

Vilya uses AI to design de novo macrocycles, including programs in oncology and immunology. It lists an integrin α4β7 program for inflammatory bowel disease, although the progress graphic does not establish a candidate-level clinical stage.

Its headquarters are in Seattle, with a South San Francisco presence. The latest financing located was a $21 million Series A expansion reported in June 2024, bringing that financing to $71 million. Vilya released Vilya-1 and Vilya-2 models in 2026. A named pharma development partner was not established.

Xaira Therapeutics combines AI models, experimental data generation and drug development in South San Francisco. Its platform includes X-Cell for target discovery and X-Design for molecule design. In October 2026 it described antibody design, laboratory automation and research-agent work.

Xaira launched with more than $1 billion in backing in April 2024. No later financing was established in the reviewed sources. They also do not establish a named lead candidate, human trial phase or named pharma discovery partnership.

XtalPi provides AI molecule design, quantum-physics modeling and robotic laboratory services for drug discovery, spanning small molecules and biologics. Its operating history describes Shenzhen research facilities, a 2024 Hong Kong listing and work with Pfizer.

Its Ailux biologics business names Lilly, Johnson & Johnson and UCB collaborations, with initial owned programs expected to enter clinical development in 2027. No single group-wide lead clinical program was established. XtalPi completed issuance of HK$2.866 billion in convertible bonds on 28 January 2026, the latest financing verified here.